



# International Journal of Chemistry and Pharmaceutical Sciences

Journal Home Page: [www.pharmaresearchlibrary.com/ijcps](http://www.pharmaresearchlibrary.com/ijcps)



Research Article

Open Access

## Synthesis Characterization and biological evaluation of 4-amino-N'-(thiazol-2-yl) benzohydrazide

\*S. Murali Krishna, Y. Padmalatha, L.K. Ravindranath, S. Chandrakala

Department of Chemistry, Sri Krishnadevaraya University, Anantapur, Andhra Pradesh, India.

### ABSTRACT

Synthesis of mannish bases derivatives containing aromatic rings were synthesized by the condensation 4-aminobenzohydrazide (1) with KSCN. It forms 2-(4-aminobenzoyl) hydrazine carbothioamide (3). The Compound (3) is treatment with substituted alpha halo ketones to obtained 4-amino-N'-(thiazol-2-yl) benzohydrazide (4). The structure of these newly synthesized compounds were characterized by  $^1\text{H}$  NMR,  $^{13}\text{C}$ NMR, Mass, IR, and elemental analysis.

**Keywords:** KSCN, DMF, Hydrazine Hydrate, Alpha Halo Ketones

### ARTICLE INFO

#### CONTENTS

1. Introduction . . . . .	1476
2. Materials and Methods . . . . .	1477
3. Results and discussion . . . . .	1477
4. Conclusion . . . . .	1479
5. Acknowledgement. . . . .	1479
6. References . . . . .	1479

**Article History:** Received 24 October 2014, Accepted 27 December 2014, Available Online 27 January 2015

#### \*Corresponding Author

S. Murali Krishna  
Department of Chemistry,  
Sri Krishnadevaraya University,  
Anantapur, Andhra Pradesh, India  
Manuscript ID: IJCPS2409



PAPER-QR CODE

**Citation:** S. Murali Krishna, et al. Synthesis Characterization and biological evaluation of 4-nitro-N-phenyl benzamide and (4-nitrophenyl) (piperidin-1-yl) methanone. *Int. J. Chem, Pharm, Sci.*, 2015, 3(1): 1476-1479.

**Copyright** © 2015 S. Murali Krishna, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

### 1. Introduction

Dermatophytes are infections of keratinized tissue, that is, the epidermis, hair and nails, caused by a group of specialized fungi. The dermatophytes do not invade

subcutaneous or deep tissue. *Dermatophyte-Trichophyton schoenleinii* was the first microorganism that was proven to cause an infectious disease of humans [1]. The

dermatophytes species can be categorized as an ecological basic as being geophilic, zoophilic or anthrophilic [2].

The geophilic species are natural habitats in the soil, natural habitats of the zoophilic dermatophytes are domestic and wild animals [3]. *Geotrichum candidum* was believed to be part of the normal flora of human skin and gastrointestinal tract. *Geotrichum* is frequently isolated from milk and is recorded as a spoilage organism on dairy products [4]. Some fungi are parasitic, especially on plants and others are symbiotic with roots and algae [5]. Fungi cells are quite different from plant cells not only by lacking chloroplasts but also by having a cell wall that contains chitin and not cellulose [6]. Thiazole and its derivatives have attracted much attention because of their unique structure and applications as antihypertensive, antiallergic, antibiotic and anticonvulsant agents [7-14]. Development of chemistry has been largely associated with wide scale of applications of these classes of compounds in medicine, biochemistry, agriculture [15-18] and also a large number of medicinally

## 2. Materials and Methods:

Melting points were determined on open capillaries using a Centex melting point apparatus .T.L.C. analysis were performed on precoatedsilicagel (E-Merck Kieselgel 60 F<sub>254</sub>) plates and visualization was done by exposing to iodine vapor .Solvent were purified by standard procedures before use .Column chromatography was conducted by using Silica gel with different solvent systems as elutes.

IR Spectra were recorded KBr on Perkin –Elmer spectrum BX series FTIR spectrometer.H<sup>1</sup>-NMR spectrum were recorded on Varian Gemini 300MHz and 200MHz spectrometers using TMS as internal standard(chemical shifts in & ppm) C<sup>13</sup>NMR spectra were recorded on a bucker 75MHz spectrometer . mass spectra were scanned on a Varian MATCH -7 and Joel JMSD-300 mass spectrometer at 70ev. elemental analysis were carried out on caroler 106 and per kin –analyzer. All the chemicals used in the present investigation were purchased from Aldrich chemicals, U.S.A. in dole- 3-carbaldehyde was prepared by a reported method.

## 3. Results and Discussion

### Synthesis of methyl 4-aminobenzoate (1)


A mixture of(b) (0.01mole) and excessive of con.HCl (15ml) and tin chloride monohydrate (0.05mol) was refluxed for two hours. The reaction progress was monitored by T.L.C. After completion of reaction cool at RT then filtered celite bed and concentrated the filtrate under reduced pressure to get color less solid.M.P.125<sup>0</sup>C, yield 65 %

**<sup>1</sup>H NMR spectra (300MHZ,(CD)<sub>2</sub> SO,TMS):** 7.19-7. 55 (m,4H,due to 4H of Benzene ring,), 2.25(S,due to 2H of –NH<sub>2</sub>) , 3.99((S,due to 3H of –CH<sub>3</sub>)

**IR spedtra:** The compound (C) shows signals at, 1690(C=N), 1790 (-C=O), 3500(-NH<sub>2</sub>), 3250(-NH)

important thiazole heterocyclic incorporated drugs approved by the FDA [19-20]. The medicinal activity of thiazole functionality is due to its ability to serve as bioequivalent (bioisostere) of the carboxylic acid group. 1, 5-disubstituted thiazole can be used as isosteres of the *cis*-amide bond of peptides [21-23].

Biphenyl thiazole compounds play important role in the medicinal chemistry. Losartan was described as the first non-peptide AT1 receptor antagonist and the coined group name was sartans [24-25]. Most of these compounds share the biphenyl thiazole unit or replacements thereof with the original advanced lead Losartan [26]. All these sartan drugs contain some common structural features represented by a biphenyl fragment bearing an acidic moiety linked to thiazole and its derivatives have attracted much attention because of their unique structure and applications as antihypertensive a heteroaromatic or acyclic system by means of a methylene group.



compd	4(a)	4(b)	4(c)	4(d)	4(e)	4(f)
R	H	Cl	OCl	Cl	NO <sub>2</sub>	Cl
R <sup>1</sup>	H	H	H	H	H	H

SCHEME 1

### Synthesis of 4-aminobenzohydrazide (2)

A solution of 1 (0.01mol) and hydrazine hydrate (0.015) in ethanol (20ml) was refluxed for 5 hours. The reaction mixture was cooled and poured in to ice-cold water with stirring. The separated solid was filtered, washed with water and recrystallised from ethanol.

**<sup>1</sup>H NMR spectra (300MHZ,(CD)<sub>2</sub> SO,TMS):** 7.10-7. 25 (m, 4H,due to 4H of Benzene ring,), 2.55(S,due to 2H of –NH<sub>2</sub>) , 8.55(S,due to 1H of –NH)

IR spedtra, the compound (1) shows signals at, 1690 (C=N), 1790 (-C=O), 3500(-NH<sub>2</sub>), 3250(-NH)

### Synthesis of 2-(4-aminobenzoyl) hydrazine carbothioamide (3)

A mixture of 4-aminobenzohydrazide (2) (0.5212gr, 0.01563 mol), potassium thiocyanate (1.96gr, 0.02mol),

con.HCl (1ml),ethyl alcohol (10ml) and water (20ml) were refluxed for three hours. The solid obtained after cooling was collected by filtration, washed with water, dried and recrystallised from ethanol-DMF mixture to afford 2-(4-aminobenzoyl) hydrazine carbothioamide (3)

**<sup>1</sup>H NMR spectra(300MHZ,(CD)<sub>2</sub> SO,TMS):** 6.10(S, due to 2H of -NH<sub>2</sub>),8.35(S,1H,due to the-NH attached to keto group),6.65-7.95(m,4H attached to the benzene ring), 4.95(s.1H attached to NH of thiazole ring),7.73(s.1H attached to amide group)

**IR spedtra:** The compound (3) shows signals at, 1660(C=N), 1790 (-C=O), 3500(-NH<sub>2</sub>), 3250(-NH)

**Synthesis of 4-amino-N'-(thiazol-2-yl)benzohydrazide(4)**

A mixture of 2-(4-aminobenzoyl) hydrazine carbothioamide (3) (0.3012gr, 0.0007675mol), in DMF(10ml) and various bromoacetyl derivatives (1.9904gr, 0.01mol)in ethanol (10ml),was stirred at room temperature for 1-2 hours. The solid separated was filtered, dried and recrystallized from ethanol –DMF mixture.

**<sup>1</sup>H NMR spectra(300MHZ,(CD)<sub>2</sub> SO,TMS):** ;, 6.20(S,due to 2H of -NH<sub>2</sub>),8.05(S,1H,due to the-NH attached to keto group),6.25-7.75(m,4H attached to the benzene ring), 4.25(s.1H attached to NH of thiazole ring),6.55-7.45(s,2H attached to thiazole ring)

**IR spedtra:** The compound (4) shows signals at, 1690(C=N), 1720 (-C=O), 3570(-NH<sub>2</sub>), 3150(-NH)

**Table 1:** Charactrization of above compounds

Compound	Molecular formulae	Yield	M.P.O <sup>o</sup> C	% of Analysis					
				C		H		N	
				Calcd	Found	Calcd	Found	Calcd	Found
1	C <sub>8</sub> H <sub>9</sub> NO <sub>2</sub>	60%	210	68.85	68.82	6.05	6.01	7.65	7.64
2	C <sub>7</sub> H <sub>9</sub> N <sub>3</sub> O	54%	223	69.47	69.44	6.36	6.31	7.4	7.36
3	C <sub>8</sub> H <sub>10</sub> N <sub>4</sub> OS	65%	215	66.66	66.64	6.1	6.06	7.5	7.07
4	C <sub>10</sub> H <sub>10</sub> N <sub>4</sub> OS	62%	205	63	62.91	5.28	5.25	7.00	6.99

#### Anti-Bacterial Activity:

The anti bacterial activity of synthesized compounds was studied by the disc diffusion method against the following pathogenic organisms. The gram-positive bacteria screened were staphylococcus aureus NCCS 2079 and Bacillus cereus NCCS 2106. The gram negative bacteria screened were Escherichia coli NCCS 2065 and pseudomonas aeruginosa NCCS 2200. The synthesized compounds were used at the concentration of 250 µg/ml and 500µg/ml using DMSO as a solvent the cefaclor 10µg/ml disc was used as a standard .(Himedia, Laboratories Ltd, Mumbai).

The test results presented in the table -2,suggest that 4a,4d,4e exhibit high activity against the tested bacteria, the rest of the compounds were found to be moderate active against the tested microorganisms.

#### Antifungal activity

The antifungal activity of synthesized compounds were studied by disc diffusion method against the organisms of aspergillus niger NCCS1196 and candida albicans NCCS34471 Compounds were treated at the concentrations of 500µg/ml and 1000µg/ml using DMSO as solvent. The standard used was clotrimazole 50µg/ml against both organisms.The test results were presented in the table-3.

**Table 2:** Antibacterial activity by disc diffusion method for phenyl thiazole 4(a.f)

Compound	Zone of inhibition (mm)			
	Staphylococcus aureus	Bacillus cereus	Escherichia coli	Pseudomonas aeruginosa
4a	12	17	16	14
4b	14	11	15	10
4c	13	12	10	09
4d	16	17	12	11
4e	18	16	15	17
4f	11	14	13	12
Cefaclor	19	22	19	20

**Table 3:** Antifungal activity by disc diffusion method for phenyl thiazole 4(a.f)

Compound	Zone of inhibition (mm)	
	Asperigillus niger	Candida albicans
4a	14	16
4b	15	13
4c	17	15
4d	18	17
4e	23	21
4f	15	13
Clotrimazole	25	25

#### 4. Conclusion

- Furthermore the substitution with phenyl group having a chloro group at p-position showed better activities.

#### 5. Acknowledgement

- My sincere thanks to UGC authorities for providing financial assistance to continue research in better manner
- I am very thankful to S.K. University authorities for providing such an environment for doing better research very much.

- Mannish bases and its derivatives were found to play an important role in medicinal chemistry as herbicidal, fungicidal, bacterial, anti-inflammatory.

- It's my pleasure to express my thanks to Department of Chemistry for giving an opportunity to do research.
- I express my sincere thanks to Prof LK Ravindranath, who is giving valuable guidance during my research.

#### 6. References

1. Bulmer, G. S., Introduction to medical mycology, 2nd Ed., Benjamin cumiimmgs publishing, London, **2002**, pp. 80–100.
2. Cruick Shank .R, Duguid. J.P, Marmion.B.P, and swain R.T, Medicinal Microbiology, 12th edition, churchil Livingstone, London, **1975**, pp.196.
3. Iro A., Athina , G., Paola,V., and Franca, Z. "Synthesis and biological evaluation of sulfonamide thiazole derivatives as antimicrobial agents", J. chem., Vol.3. No.13, pp.267-273.
4. Janssen, A. M., Scheffer, J. C. and Svendsen, A. B. "Antimicrobial activity of essential oils", J. plan. Med., **2002**, 53(5): 395-398.
5. McEvoy, G. K., Drug information.. "American society of health-system pharmacists", J. Inc., **2006**, 5(1): 91-96.
6. Narayana, B., Vijaya Raj, K.K, Ashalatha, B.V, Suchetha, K. and Sarojini, B.K., "ombination antifungal therapy", Eur. J. Med. Chem., **2004**, 39(15): 867.
7. L. V. Myznikov, A. Hrabalek, G. I. Koldobskii, *Chem. Het. Compounds*, **2007**, 43, 1-9.
8. M. J. Schocken, R. W. Creekmore, G.Theodoridis, G. J. Nystrom, R. A. Robinson, *Appl. Environ. Microbiol.*, **1989**, 55(5): 1220-1222.
9. R. N. Butter , A. R. Katritzky, C. W. Rees, *Comprehensive heterocyclic chemistry*, Vol.5: Part 4A, Pergamon Press, New York, **1984**, 001-791.
10. T. Mavromoustakos , A. Kolocouris, M. Zervou , P. Roumelioti, J. Matsoukas, R. Weisemann, J. Med. Chem., **1999**, 42: 1714-1722.
11. N. Mekni, A. Bakloiti, J. Fluorine Chem., **2008**, 129: 1073-1075.
12. J.H. Toney , P.M.D. Fitzgerald, N. Grover-Sharma, S.H.Olson, W.J. May, J.G. Sundelof, D. E. Venderwall, K.A. Cleary, S. K. Grant, J.K. Wu, J.W. Kozarich, D. L. Pompliano , G.G. Hammond, *Chem. Biol.*, **1998**, 5: 185-196.
13. Y. Tamura, F. Watanabe, T. Nakatani, K. Yasui, M. Fuji, T. Komurasaki, H. Tsuzuki, R. Maekawa, T.Yoshioka, K. Kawada, K. Sugita, M. Ohtani, J. Med. Chem., **1998**, 41: 640-649.
14. S. J. Lim , Y. Sunohara, H. Matsumoto, J. Pestic. Sci., **2007**, 32: 249-254.
15. R. N. Butler, *Advances in Heterocyclic Chemistry*, **1977**, 21: 323-435.
16. H. Singh, A.S. Chawla , V.K. Kapoor, D. Paul, R.K. Malhotra, *Progr. Med. Chem.*, **1980**, 17, 151-183.
17. H. W. Jun, *J. Pharma. Sci.*, **1976**, 65, 1038-1040.
18. A.R. Modarresi Alam, M. Nasrollahzadeh, *Turk J. Chem.*, **2009**, 33, 267-280.
19. A.R. Katritzky, R. Jain, R. Petrukhin, S. Denisenko, T. Schelenz, *Environ. Res.*, **2001**, 12: 259-266.
20. S. G. Hiriyanna , K. Basavaiah, V. Dhayanithi, A. Bindu, P. Sudhaker , H.N. Pati, *Anal. Chem. Indian J.*, **2008**, 7: 568-572.
21. G. D. Smith, J. Zabrocki, T.A. Flak, G.R. Marshal, *Int. J. Peptide Protein Res.*, **1991**, 37, 191-197.
22. K-L. Yu, R.L. Johnson, *J. Org. Che.*, **1987**, 52, 2051-2059.
23. J.V. Duncia, A.T. Chiu, D.J. Carini, G.B. Gregory, *J. Med. Chem.*, **1990**, 33: 1312-29.
24. Z.H. Israili, *J. Hum. Hypertension*, **2000**, 14, S73-S86.
25. J.L. Juillerat, J. Celerier, C. Chapuis Bernasconi, G. Nguyen, W. Wostl, H.P. Maerki, R.C. Janzer, P. Corvol, J.M. Gasc, *Br. J. Cancer*, **2004**, 90: 1059-1068.
26. P.B. Mohite, R.B. Pandhare, S.G. Khanage, V.H. Bhaskar, *Digest Journal of Nanomaterials and Biostructures*, **2009**, 4: 803-807.